All In Biotech

Free tool

FAERS Monitor: Isturisa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212801 or its brand name (Isturisa, Osilodrostat Phosphate). Reports on generic versions are filed under their own applications.

Reports

2,214

Serious

1,554

70% of reports

Hospitalization

791

Death reported

294

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use376
  • fatigue305
  • nausea260
  • death152
  • adrenal insufficiency142
  • headache142
  • asthenia129
  • diarrhoea125
  • dizziness120
  • decreased appetite114
  • vomiting109
  • cortisol decreased88
  • arthralgia78
  • disease progression76
  • covid-1973

Reports by year received

View as table
YearReports
20181
2020160
2021148
2022268
2023281
2024400
2025544
2026412

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,945 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cortisol decreasedSignal88793.1640.763,534
adrenal insufficiencySignal142112.595.815,404
disease progressionSignal766.14.9321
decreased appetiteSignal1144.73.9328
off label useSignal3764.13.7909
covid-19Signal734.03.2159
fatigueSignal3053.73.4628
astheniaSignal1293.32.8203
nauseaSignal2603.12.8387
dizzinessSignal1202.31.988
vomitingSignal1092.21.872
headacheSignal1422.21.889
diarrhoea1251.81.649
arthralgia781.81.427
death1521.71.443

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.